Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD

Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD
ShareXFacebook

(MedPage Today) -- NEW ORLEANS -- Treatment with survodutide led to significant weight loss and reductions in liver fat in phase III trials of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), but about a fifth of...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

NICU Babies More Likely to Miss Rotavirus Vax
MedPage Today

NICU Babies More Likely to Miss Rotavirus Vax

(MedPage Today) -- For U.S. kids born after the rotavirus vaccine was introduced, recommendations against administration in the neonatal intensive care unit (NICU) appeared to be a strong barrier to getting immunized, researchers reported. Children...

Read more →
Advertisement